Children's Tumor Foundation
0 Views
administrator
07/10/23
Annette Bakker, PhD, President and Chief Scientific Officer, of the Children's Tumor Foundation discusses how her company works with the pharma and biotech industries, specifically SpringWorks Therapeutics.
SpringWorks Therapeutics is planning to initiate a Phase 3 program to establish safety and efficacy of nirogacestat (PF-03084014), its gamma-secretase inhibitor, and will work collaboratively with the Desmoid Tumor Research Foundation to enable the needs of the patient community to be addressed.
-
Category
Show more
Facebook Comments
No comments found